Home
Search

Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
BIO Letter to HRSA on 340B Rebate Model
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
Learn more
CSBA Letter to Congressional Leadership on…
Learn more
BIO Comments to the USPTO’s MAY 10, 2024 Proposed…
BIO submitted these comments in response to the United States Patent and Trademark Office’s May 10, 2024, Notice of Proposed Rulemaking regarding Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting.
Learn more
All Letters, Testimony & Comments
  • Show All
Search
Results
BIO Letter to House Appropriations Committee on Priorities for Fiscal Year 2023 Interior, Environment, and Related Agencies Appropriations Act
April 28, 2022
BIO supports public policies centered on innovation to incentivize the adoption of cutting-edge technologies and practices and benefit rural economies. Further, it is crucial that the government establishes risk-proportionate, transparent…
BIO Letter to House Appropriations Committee on Priorities for Fiscal Year 2023 Energy and Water Development and Related Agencies Appropriations Act
April 28, 2022
The Biotechnology Innovation Organization (BIO) is the largest biotechnology trade association, representing approximately 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United…
BIO Letter to House Appropriations Committee on Priorities for Fiscal Year 2023 Labor, Health and Human Services, Education and Related Agencies Appropriations Act
April 28, 2022
The Biotechnology Innovation Organization (BIO) is the largest biotechnology trade association, representing approximately 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United…
BIO Letter to House on Key Priorities for Fiscal Year 2023 Agriculture, Rural Development, FDA and Related Agencies Appropriations Act
April 28, 2022
BIO represents 1,000 members in a biotech ecosystem with a central mission – to advance public policy that supports a wide range of companies and academic research centers that are working to apply biology and technology in the energy, agriculture,…
BIO Comments on Upcoming ODAC Pediatric Oncology Subcommittee Meeting
April 27, 2022
On Wednesday, April 27th, BIO submitted comments regarding an upcoming meeting of ODAC’s Pediatric Oncology Subcommittee on PREA Waivers for Same-in-Class Drugs. In particular, the subcommittee will meet to discuss the development of a conceptual…
BIO Joins Letter to Congress Supporting Funding for DOE's BETO
April 26, 2022
As a diverse set of stakeholders dedicated to building a cleaner, more resilient aviation industry, we write today to urge your committees to prioritize funding for federal programs that will help develop and scale up the sustainable aviation fuel …
BIO Joins Letter to Congress Supporting SAF Blenders Tax Credit
April 22, 2022
As a broad coalition of aviation industry stakeholders—including passenger and cargo carriers, clean fuel producers, engine and aircraft manufacturers, labor unions, airports, business and general aviation, airline passengers, trade…
BIO Comments on China's Proposed Rules for the Implementation of Regulations on Management of Human Genetic Resources
April 21, 2022
The Biotechnology Innovation Organization (BIO) welcomes the opportunity to provide comments on the proposed Rules for the Implementation of Regulations on Management of Human Genetic Resources (HGR). BIO acknowledges the efforts of the Division of…
BIO Leads Letter to Congressional Appropriations Committees for FDA Funding on Plant Biotech
April 19, 2022
The farmers, cooperatives, researchers, retailers, seed producers, scientists, and technology developers represented by the organizations below write to express our strong support for the inclusion of language in the Fiscal Year 2023 (FY 2023)…
BIO Submits Comments on CDC Clinical Practice Guideline for Prescribing Opioids
April 11, 2022
On Monday, April 11th, BIO also submitted comments in response to the CDC’s recently published Clinical Practice Guideline for Prescribing Opioids. In the comments submitted, BIO primarily requested that the CDC revise its language referencing…